Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TMCI
stocks logo

TMCI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
61.76M
-10.11%
-0.150
+1399.4%
52.02M
-1.05%
-0.230
-8%
47.40M
+0.02%
-0.244
-12.69%
Estimates Revision
The market is revising Downward the revenue expectations for Treace Medical Concepts, Inc. (TMCI) for FY2025, with the revenue forecasts being adjusted by -6.69% over the past three months. During the same period, the stock price has changed by -61.79%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+16.27%
In Past 3 Month
Stock Price
Go Down
down Image
-61.79%
In Past 3 Month
Wall Street analysts forecast TMCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMCI is 5.47 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast TMCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMCI is 5.47 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
1 Sell
Hold
Current: 2.740
sliders
Low
4.00
Averages
5.47
High
7.50
Current: 2.740
sliders
Low
4.00
Averages
5.47
High
7.50
Truist
Richard Newitter
Hold
downgrade
$7 -> $4
2025-11-10
Reason
Truist
Richard Newitter
Price Target
$7 -> $4
2025-11-10
downgrade
Hold
Reason
Truist analyst Richard Newitter lowered the firm's price target on Treace Medical to $4 from $7 and keeps a Hold rating on the shares after its Q3 results and updated outlook. The guide-down implies a return to negative revenue growth in Q4 as contribution from new osteotomy product launches are masked by incremental share loss in core lapiplasty, the analyst tells investors in a research note.
UBS
Neutral
downgrade
2025-11-07
Reason
UBS
Price Target
2025-11-07
downgrade
Neutral
Reason
UBS lowered the firm's price target on Treace Medical to $5.85 from $6.50 and keeps a Neutral rating on the shares.
Lake Street
Ben Haynor
Buy
downgrade
$12
2025-11-07
Reason
Lake Street
Ben Haynor
Price Target
$12
2025-11-07
downgrade
Buy
Reason
Lake Street analyst Ben Haynor lowered the firm's price target on Treace Medical to $7.50 from $12 and keeps a Buy rating on the shares. A roughly 10% sales decline is now implied for Q4 where the firm and consensus had previously modeled growth of about 13%, notes the analyst, who adds that there is "no question updated guidance for FY2025 represented a massive disappointment."
Stifel
Hold
downgrade
$6 -> $5
2025-11-07
Reason
Stifel
Price Target
$6 -> $5
2025-11-07
downgrade
Hold
Reason
Stifel lowered the firm's price target on Treace Medical to $5 from $6 and keeps a Hold rating on the shares. The company's Q3 and 2025 guidance update were more complicated than anticipated, as sales did outperform, but management indicated on the call that ta distributor order of roughly $6M made Q3 appear better than the underlying business reality, the analyst tells investors in a research note. The firm noted, however, that CEO John Treace did highlight several factors that support the potential for both more consistent execution and an improved outlook ahead.
JPMorgan
Lilia-Celine Lozada
Neutral -> Underweight
downgrade
$8 -> $5
2025-11-07
Reason
JPMorgan
Lilia-Celine Lozada
Price Target
$8 -> $5
2025-11-07
downgrade
Neutral -> Underweight
Reason
JPMorgan analyst Lilia-Celine Lozada downgraded Treace Medical to Underweight from Neutral with a price target of $5, down from $8. The company's earnings update is "disappointing" as the better than expected quarter was overshadowed by a reset to guidance as softness in the foot and ankle market, a shift away from Lapiplasty, and a mix headwind from new launches are set to pressure revenues in the near-term, the analyst tells investors in a research note. The firm sees multiple headwinds pressuring Treace Medical's near-term growth "and no clear timing of resolution."
BTIG
Buy -> Neutral
downgrade
2025-11-07
Reason
BTIG
Price Target
2025-11-07
downgrade
Buy -> Neutral
Reason
BTIG downgraded Treace Medical to Neutral from Buy without a price target. The company's implied Q4 outlook was "surprisingly bad," the analyst tells investors in a research note. The firm says Treace's "sudden and sizable" guidance reduction to fiscal 2025 estimates suggests a "massive slowdown" in Q4. Physicians are not taking to Lapiplasty as quickly as they are opting for minimally invasive surgery offerings against the backdrop of a weakening macroenvironment, contends BTIG.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Treace Medical Concepts Inc (TMCI.O) is -3.22, compared to its 5-year average forward P/E of -31.61. For a more detailed relative valuation and DCF analysis to assess Treace Medical Concepts Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-31.61
Current PE
-3.22
Overvalued PE
2.21
Undervalued PE
-65.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
35.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
530.60
Undervalued EV/EBITDA
-460.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.77
Current PS
0.00
Overvalued PS
9.80
Undervalued PS
1.75
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TMCI News & Events

Events Timeline

(ET)
2025-11-06
18:20:04
Treace Medical lowers FY25 revenue forecast to $211M-$213M, down from $224M-$230M.
select
2025-11-06
18:19:00
Treace Medical announces Q3 EPS of 26 cents, falling short of consensus estimate of 27 cents.
select
2025-08-07 (ET)
2025-08-07
17:38:15
Treace Medical backs FY25 revenue view $224M-$230M, consensus $227.03M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-01Globenewswire
Johnson Fistel, PLLP Probes Allegations for Long-Term Investors in Quantum Computing Inc. (QUBT), Quanex Building Products Corporation (NX), Treace Medical Concepts, Inc. (TMCI), and BigBear.ai Holdings, Inc. (BBAI)

  • Investigation of Corporate Governance: Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by officers and directors of Quantum Computing Inc., Quanex Building Products Corporation, Treace Medical Concepts, and BigBear.ai Holdings, focusing on corporate governance reforms.

  • Quantum Computing Inc. Allegations: A securities class action complaint against Quantum Computing alleges misleading statements regarding its technology capabilities, relationships with NASA, and undisclosed related party transactions, which could negatively impact the company's reputation and business.

  • Quanex Building Products Allegations: The complaint against Quanex claims that the company made false statements about its maintenance practices in Mexico, leading to significant degradation of equipment and potential financial repercussions.

  • Treace Medical and BigBear.ai Allegations: Treace Medical faces allegations of failing to disclose competitive impacts on its primary product, while BigBear.ai is accused of maintaining deficient accounting practices that led to inaccurate financial statements and potential restatements.

[object Object]
Preview
6.0
11-08NASDAQ.COM
UBS Keeps Neutral Rating on Treace Medical Concepts (TMCI)

  • UBS Coverage and Price Forecast: UBS has maintained a Neutral recommendation for Treace Medical Concepts (TMCI) as of November 7, 2025, with an average one-year price target of $8.67/share, indicating a potential upside of 94.39% from its current price of $4.46/share.

  • Projected Revenue and EPS: Treace Medical Concepts is projected to achieve annual revenue of $266 million, reflecting a 21.55% increase, while the expected non-GAAP EPS is -0.59.

  • Fund Sentiment and Ownership Changes: There are 257 funds reporting positions in TMCI, with a slight decrease in ownership by 3.02% over the last quarter. The average portfolio weight for these funds is 0.08%, which has increased by 1.55%.

  • Shareholder Activity: Notable changes in shareholder allocations include Armistice Capital increasing its stake by 0.78%, while CIBC Private Wealth Group and Jpmorgan Chase significantly reduced their holdings by 35.91% and 89.97%, respectively.

[object Object]
Preview
4.5
11-08Benzinga
Nasdaq Drops More Than 100 Points as US Consumer Sentiment Declines in November

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow up slightly by 0.06%, while the Nasdaq fell by 0.45% and the S&P 500 dropped by 0.04%.

  • Sector Movements: Energy shares increased by 1.2%, while communication services stocks saw a decline of 1.8%.

  • Consumer Sentiment Index: The University of Michigan's consumer sentiment index fell to 50.3 in November, down from 53.6 the previous month, missing market expectations.

  • Notable Stock Movements: Motorsport Games Inc. shares surged by 79% after positive sales results, while AirSculpt Technologies Inc. shares plummeted by 42% due to disappointing financial results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Treace Medical Concepts Inc (TMCI) stock price today?

The current price of TMCI is 2.74 USD — it has increased 2.24 % in the last trading day.

arrow icon

What is Treace Medical Concepts Inc (TMCI)'s business?

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.

arrow icon

What is the price predicton of TMCI Stock?

Wall Street analysts forecast TMCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMCI is 5.47 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Treace Medical Concepts Inc (TMCI)'s revenue for the last quarter?

Treace Medical Concepts Inc revenue for the last quarter amounts to 50.21M USD, increased 11.37 % YoY.

arrow icon

What is Treace Medical Concepts Inc (TMCI)'s earnings per share (EPS) for the last quarter?

Treace Medical Concepts Inc. EPS for the last quarter amounts to -0.26 USD, increased 4.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Treace Medical Concepts Inc (TMCI)'s fundamentals?

The market is revising Downward the revenue expectations for Treace Medical Concepts, Inc. (TMCI) for FY2025, with the revenue forecasts being adjusted by -6.69% over the past three months. During the same period, the stock price has changed by -61.79%.
arrow icon

How many employees does Treace Medical Concepts Inc (TMCI). have?

Treace Medical Concepts Inc (TMCI) has 477 emplpoyees as of December 05 2025.

arrow icon

What is Treace Medical Concepts Inc (TMCI) market cap?

Today TMCI has the market capitalization of 175.22M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free